FTSE MIB
33.629,21 -107,19 (-0,32%) Dow Jones
38.675,68 +450,02 (+1,18%) Nasdaq
16.156,33 +315,37 (+1,99%) Nikkei 225
38.236,07 -37,98 (-0,10%) Petrolio
77,99 -0,96 (-1,22%) Bitcoin EUR
59.171,42 -141,28 (-0,24%)
Ovid Therapeutics Inc. (1OT.F)
| Chiusura precedente | 2,8200 |
| Aperto | 2,8400 |
| Denaro | 2,8000 x 0 |
| Lettera | 2,8600 x 0 |
| Min-Max giorno | 2,8400 - 2,8400 |
| Intervallo di 52 settimane | 2,4600 - 3,6800 |
| Volume | |
| Media Volume | 0 |
| Capitalizzazione | 201,946M |
| Beta (5 anni mensile) | 0,69 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,7000 |
| Prossima data utili | 06 mag 2024 - 08 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 4,75 |
GlobeNewswireOvid Therapeutics to Present at the Jefferies Biotech CNS/Neuro Summit
NEW YORK, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today announced that management will participate in a presentation at the Jefferies Inaugural Biotech CNS/Neuro Summit on Thursday, October 12, 2023, at 3:30 p.m. ET in New York. A live webcast of the Jefferies presentation can be accessed through the Events & Presentation
- GlobeNewswire
Ovid Therapeutics to Host Investor Event - R&D Day on Monday, October 2, 2023
NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today announced that it will host a Research & Development (R&D) Day investor event on Monday, October 2, 2023. The event will take place at the Company’s headquarters in New York’s Hudson Yards from 12:00 pm - 2:30 pm and will be webcast simultaneously. Ovid management w
- GlobeNewswire
Ovid Therapeutics to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
NEW YORK, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today announced that management will participate in a panel presentation at the 2023 Cantor Fitzgerald Global Healthcare Conference on Tuesday, September 26, 2023, at 9:55 a.m. ET in New York, New York. A live webcast of the Cantor Fitzgerald presentation can be accessed
